You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Patent: 10,059,771


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,059,771
Title:Methods for treating nasal polyposis by administering an IL-4R antagonist
Abstract: The present invention provides methods for treating nasal polyposis. The methods include administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist such as an anti-IL-4R antibody or antigen binding fragment thereof.
Inventor(s): Mannent; Leda (Paris, FR), Pirozzi; Gianluca (Bridgewater, NJ), Radin; Allen (Tarrytown, NY), Gandhi; Namita A. (Tarrytown, NY), Evans; Robert (Tarrytown, NY)
Assignee: SANOFI BIOTECHNOLOGY (Paris, FR) REGENERON PHARMACEUTICALS, INC. (Tarrytown, NY)
Application Number:14/310,419
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,059,771

Introduction

When analyzing a patent, such as United States Patent 10,059,771, it is crucial to delve into several key aspects, including the historical context of patent law, the specific claims made in the patent, the current patent landscape, and the regulatory frameworks that govern patent applications. Here, we will provide a comprehensive analysis of these elements.

Historical Context of Patent Law

The U.S. patent system has a rich history, dating back to the Patent Act of 1790, which established the Patent Board consisting of the Secretary of State, Secretary of War, and Attorney General. Over the years, significant changes have been made, such as the establishment of the Patent Office as a separate entity in 1836 and its subsequent transfers to different departments, including the Department of Commerce in 1925[1].

The Patent Trial and Appeal Board (PTAB)

The 2011 Leahy-Smith America Invents Act (AIA) introduced significant changes to U.S. patent law, including the creation of the Patent Trial and Appeal Board (PTAB). PTAB is empowered to hear administrative challenges to the validity of patents, such as inter partes review (IPR) and post-grant review (PGR). These procedures are designed to improve patent quality and reduce unwarranted litigation costs, particularly targeting poor-quality patents that might fuel litigation by patent trolls[2].

Patent Security Reviews

For patents with national security implications, the Invention Secrecy Act of 1951 mandates the review of patent applications to prevent disclosure that could be detrimental to national security. The U.S. Patent and Trademark Office (USPTO) works with various defense agencies to impose Secrecy Orders if necessary, ensuring that sensitive information is not publicly released[5].

Patent Claims and Specifications

To analyze the claims of a specific patent like 10,059,771, one must examine the patent's specifications, drawings, and the scope of protection.

Claims Analysis

  • Subject Matter Eligibility: The claims must be directed to eligible subject matter under the Alice/Mayo test. This involves determining whether the claims are directed to a law of nature, natural phenomenon, or abstract idea, and if they contain an inventive concept that transforms the nature of the ineligible concept[2].
  • Novelty and Non-Obviousness: The claims must be novel and non-obvious over the prior art. This involves a thorough search of existing patents and publications to ensure the invention is new and not an obvious combination of existing technologies.
  • Written Description and Enablement: The patent must include a written description of the invention and enable one skilled in the art to make and use the invention without undue experimentation.

Specifications and Drawings

  • The specifications should provide a clear and detailed description of the invention, including any necessary drawings or diagrams. For example, in the case of a patent like US7582298B2, the specifications include detailed descriptions of the therapeutic methods and the high affinity antibodies to the human IL-6 receptor[4].

Current Patent Landscape

The current patent landscape is influenced by various factors, including technological advancements, geopolitical considerations, and regulatory changes.

Technological Advancements

  • Quantum Computing: The landscape of quantum computing patents is rapidly evolving, with key technological milestones traced through patent filings and citation analysis. This area is highly competitive, with leading countries and organizations driving innovation and geopolitical factors influencing the development and patenting of quantum technologies[3].

Geopolitical Considerations

  • The geographical distribution of patents, especially in sensitive areas like defense technology, is critical. Bilateral and multilateral agreements, such as the NATO Agreement, facilitate the reciprocal filing of classified patent applications and ensure international collaboration in defense-related technology[5].

Regulatory Frameworks

The regulatory frameworks governing patent applications are stringent and multifaceted.

USPTO Guidelines

  • The USPTO issues guidelines for patent examiners to determine whether a patent application seeks to claim ineligible subject matter. These guidelines are regularly updated to reflect changes in patent law and judicial interpretations[2].

Interagency Reviews

  • For patents with potential national security implications, interagency reviews involving the DoD, DOE, and other designated agencies ensure that sensitive information is not disclosed. The DoD Patent Application Review System (DPARS) facilitates this process[5].

Key Takeaways

  • Historical Context: Understanding the historical development of the U.S. patent system is essential for appreciating the current landscape.
  • PTAB and Administrative Challenges: The PTAB plays a crucial role in maintaining patent quality and reducing litigation costs.
  • Claims Analysis: Thorough analysis of patent claims is necessary to ensure they meet the criteria for subject matter eligibility, novelty, non-obviousness, written description, and enablement.
  • Regulatory Frameworks: Compliance with USPTO guidelines and interagency reviews is critical, especially for patents with national security implications.
  • Technological Advancements: The patent landscape is heavily influenced by technological advancements, such as those in quantum computing.

FAQs

Q: What is the significance of the Patent Trial and Appeal Board (PTAB) in U.S. patent law? A: The PTAB was created by the 2011 Leahy-Smith America Invents Act to improve patent quality and provide a more efficient system for challenging patents that should not have issued, thereby reducing unwarranted litigation costs[2].

Q: How do patent security reviews impact the disclosure of patent applications? A: Patent security reviews, mandated by the Invention Secrecy Act of 1951, prevent the disclosure of patent applications that could be detrimental to national security. This involves interagency reviews and the imposition of Secrecy Orders if necessary[5].

Q: What are the key criteria for evaluating the claims of a patent? A: The claims must be directed to eligible subject matter, novel, non-obvious, and supported by a written description that enables one skilled in the art to make and use the invention[2].

Q: How does the geographical distribution of patents influence innovation? A: The geographical distribution of patents, particularly in areas like quantum computing, is influenced by geopolitical factors and can drive international collaboration and competition in research and development[3].

Q: What role does the USPTO play in ensuring patent quality? A: The USPTO issues guidelines for patent examiners, conducts thorough reviews of patent applications, and collaborates with other agencies to ensure that patents meet the required standards and do not pose national security risks[2][5].

Sources

  1. Records of the Patent and Trademark office - National Archives
  2. The Patent Trial and Appeal Board and Inter Partes Review - Congressional Research Service
  3. Quantum Leap: Decoding Quantum Computing Innovation - Stanford Center for Responsible Quantum Technology
  4. US7582298B2 - High affinity antibodies to human IL-6 receptor - Google Patents
  5. Patent Security Reviews - Defense Technology Security Administration

More… ↓

⤷  Subscribe

Details for Patent 10,059,771

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Regeneron Pharmaceuticals, Inc. DUPIXENT dupilumab Injection 761055 March 28, 2017 ⤷  Subscribe 2034-05-07
Regeneron Pharmaceuticals, Inc. DUPIXENT dupilumab Injection 761055 October 19, 2018 ⤷  Subscribe 2034-05-07
Regeneron Pharmaceuticals, Inc. DUPIXENT dupilumab Injection 761055 June 18, 2020 ⤷  Subscribe 2034-05-07
Regeneron Pharmaceuticals, Inc. DUPIXENT dupilumab Injection 761055 June 14, 2021 ⤷  Subscribe 2034-05-07
Regeneron Pharmaceuticals, Inc. DUPIXENT dupilumab Injection 761055 October 20, 2021 ⤷  Subscribe 2034-05-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.